SEPSIS AND CAP: PARTNERSHIPS FOR DIAGNOSTICS DEVELOPMENT

Document Type:	Grants Notice
Funding Opportunity Number:	RFA-AI-04-043
Posted Date:	Aug 16, 2004
Original Due Date for Applications:	Dec 14, 2004
Current Due Date for Applications:	Dec 14, 2004
Archive Date:	Jan 13, 2005
Funding Instrument Type:	Cooperative Agreement
Category of Funding Activity:	Health
Expected Number of Awards:	Not Available.
Estimated Total Program Funding:	Not Available.
Award Ceiling:	$500,000.00
Award Floor:	none
CFDA Number:	93.855 -- Allergy, Immunology and Transplantation Research 93.856 -- Microbiology and Infectious Diseases Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

For profit organizations other than small businesses

Small businesses

Public and State controlled institutions of higher education

Private institutions of higher education

State governments

County governments

City or township governments

Special district governments

Independent school districts

Native American tribal governments (Federally recognized)

Public housing authorities/Indian housing authorities

Native American tribal organizations (other than Federally recognized tribal governments)

Others (see text field entitled "Additional Information on Eligibility" for clarification)

Additional Information on Eligibility:
Eligible agencies of the Federal Government

Agency Name

Description

Research of the National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health, strives to understand, treat and
ultimately prevent the myriad of infectious, immunologic, and allergic
diseases that threaten millions of human lives.  The NIAID supports
extramural research to control and prevent diseases caused by virtually all
infectious organisms. Studies to evaluate these organisms involve basic
biomedical research in areas of microbial physiology and antigenic structure;
applied research, including the development of diagnostic tests; and clinical
trials to evaluate experimental drugs and vaccines.

This Partnership Program will support the development and testing of
diagnostic products for selected human infectious diseases of public health
importance. A key component of the Partnership initiatives is the development
of appropriate partnerships among government, academia, and the
biotechnology, chemical or pharmaceutical industries.

Investment by industry in new diagnostics for the control of a number of
infectious diseases of public health importance remains limited.  This
initiative seeks to stimulate industry participation in decreasing the
medical impact of important targeted diseases.

This RFA is specifically focused on:

1) Development of diagnostics for early detection of the common causes of
sepsis and bacteremia or candidemia; and
2) Development of diagnostics for early detection of pathogens that commonly
cause community acquired pneumonia (CAP)

Link to Full Announcement

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-04-043.html

If you have difficulty accessing the full announcement electronically, please contact:

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster NIH OER Webmaster

• HHS NIH listed by [Posted Date]
• HHS Agencywide listed by [Posted Date]